<DOC>
	<DOCNO>NCT00544570</DOCNO>
	<brief_summary>RATIONALE : Giving high-dose chemotherapy peripheral blood stem cell transplant stop growth cancer cell stop divide kill . Giving colony-stimulating factor , G-CSF , help stem cell move bone marrow blood collect store . The stem cell return patient replace blood-forming cell destroy high-dose chemotherapy radiation therapy . PURPOSE : This clinical trial study side effect well high-dose chemotherapy work treat patient undergoing stem cell transplant recurrent refractory Hodgkin 's lymphoma .</brief_summary>
	<brief_title>High-Dose Chemotherapy Treating Patients Undergoing Stem Cell Transplant Recurrent Refractory Hodgkin 's Lymphoma</brief_title>
	<detailed_description>OBJECTIVES : - To evaluate feasibility toxicity high-dose sequential therapy comprise high-dose etoposide cyclophosphamide filgrastim ( G-CSF ) support follow 2 course high-dose therapy autologous stem cell transplantation patient poor-risk recurrent refractory Hodgkin lymphoma . - To analyze response rate , progression-free survival , overall survival patient treat regimen . - To determine percentage patient achieve minimal disease status two course Hodgkin lymphoma chemotherapy `` classical autologous stem cell transplantation . '' OUTLINE : - First high-dose chemotherapy* : Patients receive high-dose cyclophosphamide IV 2 hour follow etoposide IV 4 hour . NOTE : *Patients minimal disease ( i.e. , single lymph node ≤ 2 cm maximal horizontal diameter &gt; 75 % reduction bulky ( ≥ 10 cm ) tumor mass AND morphological evidence active bone marrow disease ) initial evaluation receive first high-dose chemotherapy proceed directly peripheral blood stem cell ( PBSC ) mobilization filgrastim ( G-CSF ) 3 day PBSC collection begin day 4 . - Peripheral stem cell mobilization collection : Patients receive G-CSF subcutaneously begin 96 hour completion etoposide continue completion PBSC collection . Patients undergo leukapheresis collect PBSC reinfusion additional high-dose therapy . - Second high-dose chemotherapy : Patients receive high-dose melphalan IV 30 minute day -1 . - First PBSC infusion : At least 24 hour completion melphalan , patient undergo reinfusion PBSC day 0 . - Local radiotherapy : Patients localized tumor mass &gt; 5 cm second course chemotherapy previous history bulky disease ( &gt; 10 cm mediastinal mass &gt; 1/3 transverse thoracic diameter ) irradiate may receive local radiotherapy 2 week , discretion principal investigator . - High-dose therapy : Eight 12 week completion second course chemotherapy , patient receive 1 2 regimen . - Regimen A : Patients undergo fractionate total body irradiation 3 time daily day -8 -5 ( 10 fraction ) receive high-dose etoposide IV 4 hour day -4 cyclophosphamide IV day -2 . - Regimen B : Patients receive high-dose carmustine IV 4 hour day -7 -5 etoposide cyclophosphamide regimen A . - Second PBSC infusion : At least 48 hour completion cyclophosphamide , patient undergo reinfusion PBSC day 0 . After completion study therapy , patient follow day 60 every 3 month 1 year .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Hodgkin Disease</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Melphalan</mesh_term>
	<mesh_term>Carmustine</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm Hodgkin lymphoma Diagnosis review participate institution Failed achieve complete remission ( CR ) firstline chemotherapy chemoradiotherapy ( i.e. , induction failure ) OR felt curable radiotherapy alone Relapsed standard chemotherapy regimen Hodgkin lymphoma AND ≥ 1 follow poorrisk feature : Extranodal disease relapse Interval first CR relapse &lt; 12 month B symptom relapse Chemoresistant relapse OR failure achieve second CR conventional nontransplantation salvage chemotherapy regimen No cytogenetic abnormality cytogenetic analysis bone marrow PATIENT CHARACTERISTICS : Inclusion criterion : SWOG performance status 01 LVEF &gt; 50 % 2DECHO MUGA scan Patients LVEF 4550 % without wall motion abnormality assess individual basis consultation cardiologist FEV_1 DLCO &gt; 45 % predict Creatinine clearance &gt; 60 mL/min HIVnegative Hepatitis B surface antigennegative Hepatitis C virusnegative ALT ≤ 5 time upper limit normal No inadequate vital organ function No active infection Fertile patient must use adequate contraception PRIOR CONCURRENT THERAPY : See Disease Characteristics Concurrent , posttransplantation , consolidative radiotherapy residual mass allow provided patient engraft WBC &gt; 4,000/μL platelet count &gt; 100,000/μL</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>64 Years</maximum_age>
	<verification_date>February 2010</verification_date>
	<keyword>recurrent adult Hodgkin lymphoma</keyword>
	<keyword>recurrent/refractory childhood Hodgkin lymphoma</keyword>
</DOC>